Skip to main content

Table 5 Comparison of baseline characteristics between the patients with EP ( +) and EP (−) after re-RT

From: Efficacy and toxicity of re-irradiation for esophageal cancer patients with locoregional recurrence: a retrospective analysis

Variables

EP (−)

EP ( + )

p

Re-RT age (years) (n, %)

  

0.693

 ≤ 60

68 (34.3)

17 (31.5)

 

 > 60

130 (65.7)

37 (68.5)

 

Gender (n, %)

  

0.955

 Male

162 (81.8)

44 (81.5)

 

 Female

36 (18.2)

10 (18.5)

 

Smoking (n, %)

  

0.965

 Yes

96 (48.5)

26 (48.1)

 

 No

102 (51.5)

28 (51.9)

 

Alcohol consumption (n, %)

  

0.206

 Yes

80 (40.4)

27 (50)

 

 No

118 (59.6)

27 (50)

 

Primary tumor location (n, %)

   

 Upper

53 (26.8)

19 (35.2)

0.225

 Middle and lower thoracic

145 (73.2)

35 (64.8)

 

Length, cm (n, %)

  

0.872

 ≤ 4

121 (61.1)

31 (57.4)

 

 4 < to ≤ 6

55 (27.8)

16 (29.6)

 

 > 6

22 (11.1)

7 (13.0)

 

Ulcerative type (n, %)

  

0.546

 Yes

109 (55.1)

25 (46.3)

 

 No

89 (44.9)

29 (53.7)

 

Tumor differentiation (n, %)

  

0.882

 Higher

29 (14.6)

7 (13.0)

 

 Middle

113 (57.1)

30 (55.6)

 

 Lower

56 (28.3)

17 (31.4)

 

T stage (n, %)

  

0.962

 T1–2

63 (31.8)

17 (31.5)

 

 T3–4

135 (61.2)

37 (68.5)

 

Initial clinical/pathological stage (n, %)

 

0.775

 I–II

91 (46.0)

26 (48.1)

 

 III–Iva

107 (54)

28 (51.9)

 

Initial treatment (n, %)

  

0.171

 RT

127 (64.1)

40 (74.1)

 

 Surgery + RT

71 (35.9)

14 (25.9)

 

Pattern of recurrence (n, %)

  

0.010

 Regional lymph node recurrence only

90 (45.4)

15 (27.8)

 

 Local failure

73 (36.9)

20 (37.0)

 

 Both

35 (17.7)

19 (35.2)

 

Recurrence-free interval (months) (n, %)

 

0.025

 ≤ 12

53 (36.8)

23 (42.6)

 

 > 12

145 (73.2)

31 (57.4)

 

Re-RT dose (Gy) (n, %), BED10

  

0.442

 ≤ 60

102 (51.5)

31 (53.7)

 

 > 60

96 (48.5)

23 (46.3)

 

Concurrent chemoradiotherapy (n, %)

 

0.894

 Yes

86 (43.4)

24 (44.4)

 

 No

112 (56.6)

30 (55.6)

 

Total radiation dose (Gy) (n, %), BED10

 

0.334

 ≤ 131.5

99 (50.0)

31 (57.4)

 

 > 131.5

99 (50.0)

23 (42.6)

 

Esophageal stenosis (n, %)

  

0.000

 Yes

68 (34.3)

34 (63.0)

 

 No

130 (65.7)

20 (37.0)

 

Fat space between tumor and adjacent tissue disappeared (n, %)

  

0.000

 Yes

37 (18.7)

27 (50.0)

 

 No

161 (81.3)

27 (50.0)

 

Pain in the chest or/and back (n, %)

  

0.175

 Yes

17 (8.6)

8 (14.8)

 

 No

181 (91.4)

46 (85.2)

 

Median BMI (n, %)

  

0.102

 ≤ 20

63 (31.8)

11 (20.4)

 

 > 20

135 (68.2)

43 (79.6)

 

Hemoglobin (n, %)

  

0.141

 ≤ 12

70 (35.4)

25 (46.3)

 

 > 12

128 (64.6)

29 (53.7)

 

Albumin (n, %)

  

0.447

 ≤ 40

66 (33.3)

21 (38.9)

 

 > 40

132 (66.7)

33 (61.1)

 

White blood cells, × 109/L

5.776 ± 2.285

6.520 ± 3.103

0.059

Neutrophil, × 109/L

4.379 ± 2.172

5.013 ± 2.936

0.090